{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yang X"],"funding":["Natural Science Foundation of Beijing Municipality","Special Program of Peking University Health Science Center","National Natural Science Foundation of China","National Key Research and Development Program of China"],"pagination":["e03534"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12677619"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(45)"],"pubmed_abstract":["Current antiviral drugs targeting the hepatitis B virus (HBV) still face challenges in achieving a functional cure for chronic hepatitis B. Therefore, it is necessary to explore new therapeutic approaches and combined therapy strategies. Anticodon engineered transfer RNA (ACE-tRNA) has been widely applied in the treatment of genetic diseases caused by nonsense mutations. However, its role in antiviral therapy has not been reported yet. In this study, ACE-tRNAs are designed to target the highly conserved stop codon (UAG) of HBV core protein (HBc). All designed ACE-tRNAs can read through the stop codon of HBc. Among them, tRNASUAG might promote HBc phosphorylation by introducing a phosphorylatable serine into the C-terminal domain of HBc, thereby potentially reducing HBc levels an"],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["Anticodon Engineered Transfer RNA (tRNA<sup>SUAG</sup>) Inhibits Hepatitis B Virus Replication by Promoting the Degradation of Core Protein."],"pmcid":["PMC12677619"],"funding_grant_id":["2023YFC2306902","7182080","BMU2021RCZX013","82172251","82372236"],"pubmed_authors":["Yang X","Liu X","Li J","Luo Z","Sun H","Wang J","Zhang Q","Song Y"],"additional_accession":[]},"is_claimable":false,"name":"Anticodon Engineered Transfer RNA (tRNA<sup>SUAG</sup>) Inhibits Hepatitis B Virus Replication by Promoting the Degradation of Core Protein.","description":"Current antiviral drugs targeting the hepatitis B virus (HBV) still face challenges in achieving a functional cure for chronic hepatitis B. Therefore, it is necessary to explore new therapeutic approaches and combined therapy strategies. Anticodon engineered transfer RNA (ACE-tRNA) has been widely applied in the treatment of genetic diseases caused by nonsense mutations. However, its role in antiviral therapy has not been reported yet. In this study, ACE-tRNAs are designed to target the highly conserved stop codon (UAG) of HBV core protein (HBc). All designed ACE-tRNAs can read through the stop codon of HBc. Among them, tRNASUAG might promote HBc phosphorylation by introducing a phosphorylatable serine into the C-terminal domain of HBc, thereby potentially reducing HBc levels an","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-07-15T12:26:22.708Z","creation":"2026-07-04T03:13:00.217Z"},"accession":"S-EPMC12677619","cross_references":{"pubmed":["40940305"],"doi":["10.1002/advs.202503534"]}}